

Ayrton Drug Manufacturing Limited

Un-audited Profit and Loss Account For the third quarter ended 30th September 2009

		2009	2008
	Notes	GH¢	GH¢
Sale of goods		10,853,798	8,502,950
		-----	-----
Revenue		10,853,798	8,502,950
Cost of Sales	2.1	(6,593,236)	(5,234,674)
		-----	-----
Gross Profit		4,260,562	3,268,276
Other income	2.12	100,919	19,985
Selling and distribution expenses	2.2	(740,590)	(563,719)
Administration and general expenses	2.3	(1,250,441)	(963,864)
		-----	-----
Operating Profit		2,370,450	1,760,678
Finance cost	2.4	(2,391)	(2,968)
Finance income		41,547	33,776
		-----	-----
Profit before taxation		2,409,606	1,791,486
Income tax expense	2.5	(587,037)	(388,939)
		-----	-----
Profit for the period		1,822,569	1,402,547
		=====	=====
Earnings per share		0.0085	0.0065

Ayrton Drug Manufacturing Limited

Un-audited Balance Sheet

As at 30th September 2009

	Note	2009 GH¢	2008 GH¢
Assets			
Non current assets			
Property, plant and equipment	2.6	2,856,446	2,807,637
Intangible assets	2.7	252,611	146,250
		-----	-----
		3,109,057	2,953,887
Current Assets			
Inventories	2.8	3,966,682	4,355,587
Trade and other receivables	2.9	3,443,805	2,324,095
Other current financial assets		0	0
Cash and bank balances	2.1	1,302,976	739,550
		-----	-----
		8,713,463	7,419,232
		-----	-----
Total assets		11,822,520	10,373,119
<hr/>			
Equity and liabilities			
Equity attributable to equity holders			
Stated capital	2.13	4,475,000	4,475,000
Other capital reserves		495,294	495,294
Income surplus		5,746,235	3,768,284
		-----	-----
Total equity		10,716,529	8,738,578
<hr/>			
Current liabilities			
Trade and other payables	2.11	875,389	1,472,475
Income tax payable	2.5	230,602	162,066
		-----	-----
Total liabilities		1,105,991	1,634,541
<hr/>			
Total equity and liabilities		11,822,520	10,373,119
<hr/>			

The financial statements do not contain untrue statements, misleading facts or omit material facts to the best of my knowledge.

Director
Samuel Adjepong

Director
Belinda Opoku (Mrs)

2

AYRTON DRUG MANUFACTURING LIMITED

Statement of Changes in Equity

For the third quarter ended 30th September 2009

	Issued Capital GH¢	Income surplus GH¢	Other reserves GH¢	Total GH¢
Balance at 1 January	4,475,000	4,353,666	495,295	9,323,961
Total recognised income and expense	0	1,822,569		1,822,569
Dividend		(430,000)		(430,000)
Balance at 30th September	4,475,000	5,746,235	495,295	10,716,530

Sep-08	Issued Capital GH¢	Income surplus GH¢	Other reserves GH¢	Total GH¢
Balance 1st January	4,475,000	2,365,858	495,294	7,336,152
Total recognised income and expense	0	1,402,547		1,402,547
Dividend (additional)		(121)		(121)
Balance at 30th September	4,475,000	3,768,284	495,294	8,738,578

Ayrton Drug Manufacturing Limited

Un-audited Cash Flow Statement

For the third quarter ended 30th September 2009

	2009 GH¢	2008 GH¢
Operating activities	2,409,606	1,791,486
Profit before tax		
Adjustment		
Adjustment to reconcile profit before tax to net cash flows:		
Depreciation of property, plant and equipment	348,472	326,333
Amortisation	24,923	3,750
Items not involving movement of cash	0	21,532
Working capital adjustments:		
Increase in inventory	556,856	(2,009,327)
Increase/decrease in trade and other receivables	(1,127,536)	(4,591)
Increase/decrease in trade and other payables	(145,596)	638,869
Income tax paid	(460,335)	(387,761)
Net cash flow from operating activities	1,606,390	380,291
Investing activities		
Proceeds from sale of property, plant and equipment	0	10,113
Purchase of property, plant and equipment	(441,258)	(559,984)
Purchase of intangible asset	(3,200)	(150,000)
Net cash flows from investing activities	(444,458)	(699,871)
Financing activities		
Dividends paid to equity holders	(430,000)	(425,700)
Fixed deposit redeemed	0	300,000
Net cash flow from financing activities	(430,000)	(125,700)
Net (decrease)/increase in cash and cash equivalent	731,932	(445,280)
Cash and cash equivalent at 1 January	571,044	1,184,830
Cash and cash equivalent at 30 September	1,302,976	739,550

